Senslide: a distributed landslide prediction system

We describe the design, implementation, and current status of Senslide, a distributed sensor system aimed at predicting landslides in the hilly regions of western India. Landslides in this region occur during the monsoon rains and cause significant damage to property and lives. Unlike existing solutions that detect landslides in this region, our goal is to predict them before they occur. Also, unlike previous efforts that use a few but expensive sensors to measure slope stability, our solution uses a large number of inexpensive sensor nodes inter-connected by a wireless network. Our system software is designed to tolerate the increased failures such inexpensive components may entail. We have implemented our design in the small on a laboratory testbed of 65 sensor nodes, and present results from that testbed as well as simulation results for larger systems up to 400 sensor nodes. Our results are sufficiently encouraging that we intend to do a field test of the system during the monsoon season in India

Therapy of childhood hypothyroidism: a reappraisal

This article does not have an abstract

Sulfonylurea Receptor 1 in Central Nervous System Injury : An Updated Review

Sulfonylurea receptor 1 (SUR1) is a member of the adenosine triphosphate (ATP)-binding cassette (ABC) protein superfamily, encoded by Abcc8, and is recognized as a key mediator of central nervous system (CNS) cellular swelling via the transient receptor potential melastatin 4 (TRPM4) channel. Discovered approximately 20 years ago, this channel is normally absent in the CNS but is transcriptionally upregulated after CNS injury. A comprehensive review on the pathophysiology and role of SUR1 in the CNS was published in 2012. Since then, the breadth and depth of understanding of the involvement of this channel in secondary injury has undergone exponential growth: SUR1-TRPM4 inhibition has been shown to decrease cerebral edema and hemorrhage progression in multiple preclinical models as well as in early clinical studies across a range of CNS diseases including ischemic stroke, traumatic brain injury, cardiac arrest, subarachnoid hemorrhage, spinal cord injury, intracerebral hemorrhage, multiple sclerosis, encephalitis, neuromalignancies, pain, liver failure, status epilepticus, retinopathies and HIV-associated neurocognitive disorder. Given these substantial developments, combined with the timeliness of ongoing clinical trials of SUR1 inhibition, now, another decade later, we review advances pertaining to SUR1-TRPM4 pathobiology in this spectrum of CNS disease-providing an overview of the journey from patch-clamp experiments to phase III trials

Thyroid hormones and TSH in normal children and hypothyroids

This article does not have an abstract

Neonatal screening for hypothyroidism

This article does not have an abstract